Literature DB >> 17086092

Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model.

István Leprán1, Piero Pollesello, Szilvia Vajda, András Varró, Julius Gy Papp.   

Abstract

The preconditioning effects of levosimendan were investigated on ischemia-reperfusion induced morphological and functional cardiac damage. Langendorff-perfused rabbit hearts were reserved as controls or subjected either to global myocardial ischemic preconditioning or to perfusion with levosimendan (0.1 micromol/l) for two 5-minute cycles. After a washout period, all hearts were then subjected to 30 minutes of global ischemia and 120 minutes of drug-free reperfusion. Intraventricular pressure and coronary flow were measured, and infarct size determined after nitroblue-tetrazolium staining on completion of the experiments. Levosimendan pretreatment resulted in a significantly smaller elevation from the preischemic level in left ventricular end-diastolic pressure during reperfusion (37 +/- 17 mm Hg) compared with controls (56 +/- 14 mm Hg) and ischemia-preconditioned hearts (53 +/- 34 mm Hg). The left ventricular developed pressure-representing the functional recovery of the heart after ischemia-that was significantly improved by levosimendan pretreatment (38 +/- 6% vs 16 +/- 5% in controls, P < 0.05). In addition, contractility and relaxability parameters (+dP/dt and -dP/dt, respectively) were better preserved in the levosimendan hearts. The volume of infarcted myocardium after global ischemia-reperfusion was significantly (P < 0.05) decreased by both ischemic preconditioning (38 +/- 2%) or levosimendan pretreatment (45 +/- 2%) versus controls (52 +/- 2%). The results of this study suggest that levosimendan pretreatment is capable of decreasing infarct size in an ischemia-reperfusion model and improving recovery of cardiac function following ex vivo global ischemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17086092     DOI: 10.1097/01.fjc.0000246151.39758.2a

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart.

Authors:  E F du Toit; A Genis; L H Opie; P Pollesello; A Lochner
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

2.  Calcium sensitisation impairs diastolic relaxation in post-ischaemic myocardium: implications for the use of Ca(2+) sensitising inotropes after cardiac surgery.

Authors:  Yeong-Hoon Choi; Douglas B Cowan; Thorsten C W Wahlers; Roland Hetzer; Pedro J Del Nido; Christof Stamm
Journal:  Eur J Cardiothorac Surg       Date:  2009-07-17       Impact factor: 4.191

Review 3.  Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.

Authors:  Ibrahim Halil Kurt
Journal:  Surg Today       Date:  2009-04-30       Impact factor: 2.549

4.  Preconditionin effects of dexmedetomidine on myocardial ischemia/reperfusion injury in rats.

Authors:  Hasan Kocoglu; Kazim Karaaslan; Ersoz Gonca; Omer Bozdogan; Nebahat Gulcu
Journal:  Curr Ther Res Clin Exp       Date:  2008-04

5.  Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.

Authors:  Elena Grossini; Kevin Bellofatto; Serena Farruggio; Lorenzo Sigaudo; Patrizia Marotta; Giulia Raina; Veronica De Giuli; David Mary; Piero Pollesello; Rosalba Minisini; Mario Pirisi; Giovanni Vacca
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

Review 6.  Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.

Authors:  László Nagy; Piero Pollesello; Zoltán Papp
Journal:  J Cardiovasc Pharmacol       Date:  2014-09       Impact factor: 3.105

Review 7.  The Role of Levosimendan in Patients with Decreased Left Ventricular Function Undergoing Cardiac Surgery.

Authors:  Marija Bozhinovska; Gordana Taleska; Andrej Fabian; Maja Šoštarič
Journal:  Open Access Maced J Med Sci       Date:  2016-06-28

8.  Levosimendan improves exercise performance in patients with advanced chronic heart failure.

Authors:  Saima Mushtaq; Daniele Andreini; Stefania Farina; Elisabetta Salvioni; Gianluca Pontone; Susanna Sciomer; Valentina Volpato; Piergiuseppe Agostoni
Journal:  ESC Heart Fail       Date:  2015-08-13

9.  Use of levosimendan in patients with heart failure in different settings: case reports and treatment guidance.

Authors:  Irina Barbici; Anders Hedman; Carl-Arne Ewaldsson
Journal:  Heart Lung Vessel       Date:  2015

10.  Preoperative optimization with levosimendan in heart failure patient undergoing thoracic surgery.

Authors:  Moana Rossella Nespoli; Marco Rispoli; Dario Maria Mattiacci; Marianna Esposito; Antonio Corcione; Carlo Curcio; Salvatore Buono
Journal:  Int J Surg Case Rep       Date:  2016-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.